Hims & Hers Health, Inc. Hits New 52-Week Low at $15.15

Hims & Hers Health, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 15.15 on February 23, 2026. This decline marks a significant downturn for the company, which has seen its stock price drop by 28.26% over the past year, contrasting sharply with the S&P 500's performance of 12.95% during the same period. Despite this recent dip, Hims & Hers has reported positive results for the last 13 consecutive quarters, showcasing a robust operating cash flow of USD 258.59 million. The company has also achieved a notable net profit of USD 48.74 million, reflecting a remarkable growth rate of 250.11%. With a market capitalization of USD 3,558 million, Hims & Hers maintains a price-to-earnings ratio of 57.00 and a return on equity of 27.23%. However, the stock's price-to-book ratio stands at 6.12, indicating a premium valuation relative to its book value. As the company navigates its current market position, these financial metrics highlight its ongoing performance amidst the recent stock price challenges.